Predicting Antidepressant Effects of Ketamine: the Role of the Pregenual Anterior Cingulate Cortex as a Multimodal Neuroimaging Biomarker

Anne Weigand, Matti Gärtner, Milan Scheidegger, Patrik O. Wyss, Anke Henning, Erich Seifritz, Anna Stippl, Ana Herrera-Melendez, Malek Bajbouj, Sabine Aust, Simone Grimm

MSB Medical School Berlin, Berlin, Germany (Drs Weigand, Gärtner and Grimm); Department of Psychiatry and Psychotherapy, Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin and Berlin Institute of Health, Berlin, Germany (Dr Gärtner, Ms Stippl, Dr Herrera-Melendez, Dr Bajbouj, Dr Aust, and Dr Grimm); Department of Psychiatry, Psychotherapy and Psychosomatics, University Hospital of Psychiatry, University of Zurich, Switzerland (Drs Scheidegger, Seifritz, and Grimm); Department of Radiology, Swiss Paraplegic Centre, Nottwil, Switzerland (Dr Wyss); and Advanced Imaging Research Center, UT Southwestern Medical Center, Dallas, Texas, USA (Dr Henning).

A.W. and M.G. contributed equally.

Correspondence: Simone Grimm, PhD, MSB Medical School Berlin, Rüdesheimer Straße 50, 14197 Berlin, Germany (simone.grimm@medicalschool-berlin.de).

Abstract

Background: Growing evidence underscores the utility of ketamine as an effective and rapid-acting treatment option for major depressive disorder (MDD). However, clinical outcomes vary between patients. Predicting successful response may enable personalized treatment decisions and increase clinical efficacy.

Methods: We here explored the potential of pregenual anterior cingulate cortex (pgACC) activity to predict antidepressant effects of ketamine in relation to ketamine-induced changes in glutamatergic metabolism. Prior to a single i.v. infusion of ketamine, 24 patients with MDD underwent functional magnetic resonance imaging during an emotional picture-viewing task and magnetic resonance spectroscopy. Changes in depressive symptoms were evaluated using the Beck Depression Inventory measured 24 hours pre- and post-intervention. A subsample of 17 patients underwent a follow-up magnetic resonance spectroscopy scan.

Results: Antidepressant efficacy of ketamine was predicted by pgACC activity during emotional stimulation. In addition, pgACC activity was associated with glutamate increase 24 hours after the ketamine infusion, which was in turn related to better clinical outcome.

Conclusions: Our results add to the growing literature implicating a key role of the pgACC in mediating antidepressant effects and highlighting its potential as a multimodal neuroimaging biomarker of early treatment response to ketamine.

Keywords: pgACC, pregenual anterior cingulate cortex, multimodal neuroimaging biomarker, ketamine, antidepressant effects
Significance Statement

A handful of studies have investigated the role of the pregenual anterior cingulate cortex (pgACC) in predicting the antidepressant effects of ketamine; however, they only explored single neuroimaging markers. We here report data from 24 major depressive disorder (MDD) patients who were investigated using both functional magnetic imaging (fMRI) during emotional processing and magnetic resonance spectroscopy (MRS) to explore the potential of pgACC activity to predict antidepressant effects of ketamine in relation to ketamine-induced changes in glutamatergic metabolism. Results show that antidepressant efficacy of ketamine was predicted by pgACC activity during emotional stimulation. In addition, pgACC activity was associated with glutamate increase 24 hours after ketamine infusion, which was in turn related to better clinical outcome. Taken together, we here provide first evidence, to our knowledge, that the pgACC can serve as a multimodal neuroimaging biomarker of early treatment response to ketamine in MDD patients.

Introduction

As the most common mental disorder with a lifetime prevalence between 15% and 20%, major depressive disorder (MDD) is the leading source of medical disability for people under the age of 45 in the developed world and has a major negative impact on public health and productivity. Even though standard antidepressant treatments are often effective, approximately 30% of patients suffering from MDD do not respond sufficiently to established pharmacological, psychotherapeutic, or somatic treatments (Bauer et al., 2013). Clearly, a better understanding of antidepressant treatment mechanisms and early prediction of response to a given treatment would help in selecting the most appropriate therapy for an individual patient and reduce the immense burden associated with depressive illness.

Among the most consistent findings in depression research are alterations of cerebral blood flow, glucose metabolism, resting state functional connectivity, and functional activation in the pregenual anterior cingulate cortex (pgACC), a region relevant for emotional processing and the establishment of mood states (Drevets et al., 2008; Pizzagalli, 2011). The pgACC is part of the default mode network (DMN; Raichle et al., 2001), and its aberrant activation with decreased negative BOLD responses (NBRs) during the performance of emotional tasks suggests depression-associated pathological abnormalities of the DMN regulate the processing of emotional material (Sheline et al., 2009; Grimm et al., 2011). Restored pgACC activity has been reported as a result of successful antidepressant drug treatment (Delaveau et al., 2011). Two meta-analyses and systematic reviews (Pizzagalli, 2011; Fu et al., 2013) as well as following studies (Godlewska et al., 2018a; Pizzagalli et al., 2018) highlight increased pgACC activity prior to treatment as a reliable biomarker of clinical response to a variety of antidepressant treatments, including pharmacotherapy, sleep deprivation, and repetitive transcranial magnetic stimulation (rTMS).

Increasing preclinical and clinical evidence underscores the role of glutamate (Glu) in the pathophysiology of depression and suggests that Glu modulation may induce rapid relief of depressive symptoms (Sanacora et al., 2012; Chadi G. Abdallah et al., 2015; Lener et al., 2017). Specifically, there is converging evidence for reduced concentrations of Glu and glutamine (Gln) in the pgACC (Walter et al., 2009; Luykx et al., 2012; Arnone et al., 2015; Shirayama et al., 2017; Wise et al., 2018; Benson et al., 2020). Because it is difficult to separate Glu clearly from its precursor and metabolite, Gln, the 2 compounds are often measured together as Glx, and, accordingly, Glx reductions have been reported in MDD (Yüksel and Öngür, 2010; Bond and Lim, 2014; Li et al., 2014; Godfrey et al., 2018; Moriguchi et al., 2019).

Altered Glu levels in the pgACC might contribute to emotional dysregulation and perseverative rumination via failure of the greater ACC circuit to properly regulate emotional responses and facilitate task-based network switching (Johansen-Berg et al., 2008; Pizzagalli, 2011). Several studies have shown that decreased pgACC Glu and Glx content normalizes after successful antidepressant treatments, including electroconvulsive therapy antidepressants (Luborzewski et al., 2007; Yang et al., 2014). Thus, modulation of glutamatergic neurotransmission might represent a shared biological pathway among diverse antidepressant treatments (Skolnick, 1999).

A growing body of evidence suggests that the pgACC is also a key locus of action for ketamine, a promising Glu-modulating drug with a rapid antidepressant effect (for a review, see Alexander et al., 2021). Several lines of investigation have shown that ketamine increases prefrontal Glu levels through N-methyl-D-aspartate (NMDA) receptor inhibition and subsequent α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor activation (Rowland et al., 2005; Stone et al., 2012; Zanos et al., 2016). Interestingly, the rapid antidepressant effect of ketamine might also be related to swift changes in task-related activity in the pgACC, as a study in healthy patients showed effects specifically during the processing of negative emotional stimuli 24 hours after ketamine administration (Lehmann et al., 2016). The importance of these ketamine-induced modulations is highlighted by studies suggesting that, similar to other antidepressant interventions, aberrant pgACC activity during emotional and cognitive processing prior to treatment identifies responders to ketamine (Salvadore et al., 2009, 2010).

This study therefore aimed to assess the potential role of the pgACC as a multimodal neuroimaging biomarker of early treatment response to ketamine using both functional MRI (fMRI) and magnetic resonance spectroscopy (MRS) in a sample of MDD patients. We hypothesized that increased pgACC activity (i.e., reduced NBRs) during emotional processing prior to treatment would predict antidepressant effects of ketamine 24 hours after the infusion. Further, we aimed to examine the relationship between neural activity and ketamine-evoked changes in Glu concentration in the pgACC.

METHODS

Participants

Data from 2 cohorts of patients suffering from MDD and treated with ketamine were included in the present study. The first was enrolled at the Department of Psychiatry and Psychotherapy, Charité-Universitätsmedizin Berlin (CHAR). The second cohort
was treated at the Department of Psychiatry, Psychotherapy and Psychosomatics, Psychiatric Hospital, University of Zurich (UZH). Major depression was diagnosed according to the criteria of the DSM-IV. There were no restrictions regarding antidepressant medication at the time of enrolment; however, medication intake was documented. Exclusion criteria were lifetime antidepressant treatment with ketamine; lifetime recreational use of ketamine; cardiovascular diseases such as hypertension, cardiac insufficiency, or myocardial infarct in the past 6 months; insufficiently treated anemia; hyper- or hypothyroidism; lifetime increased intracranial pressure or glaucoma; chronic physical diseases, in particular hepatorenal dysfunction; recent heart or head surgery; current pregnancy; as well as any relevant psychiatric or neurological comorbidity. Additional exclusion criteria regarding the scanning procedure were metallic body implants and claustrophobia. Participants gave their written informed consent before study entry. The study was carried out in accordance with the Declaration of Helsinki and was approved by the Institutional Review Board of Charité-Universitätsmedizin Berlin and the Ethics Committee Zurich.

Study Design and Ketamine Administration

All 24 MDD patients underwent fMRI and MRS prior to a single i.v. infusion of ketamine over 40 minutes administered by psychiatrists and anesthesiologists. According to clinical routine, patients treated at UZH received 0.25 mg/kg S-ketamine (Ketanest S, Pfizer, Zurich, Switzerland), and patients treated at CHAR received 0.5 mg/kg racemic ketamine (enantiomer ratio of 1:1). Because S-ketamine exerts a 3–4 times higher potency or receptor affinity than racemic ketamine, doses are typically reduced by 50% (Sinner and Graf, 2008; Hashimoto, 2019).

For clinical assessment of depression severity at baseline, the Montgomery Asberg Depression Rating Scale was used at CHAR (Montgomery and Åsberg, 1979) and the Hamilton Depression Rating Scale at UZH (Hamilton, 1980). At both sites, treatment outcome was assessed by self-report of depressive symptoms using the Beck Depression Inventory (BDI) measured 24 hours pre- and post-intervention. A subsample of 17 patients underwent a follow-up MRS scan. The 24-hour follow-up time point was based on the observation that antidepressant effects of ketamine are most pronounced 1 day post administration (Zarate et al., 2006).

fMRI Paradigm

The fMRI paradigm was a passive viewing task consisting of 80 different photographs (40 positive and 40 negative) from the International Affective Picture System (IAPS) (Lang et al., 1997). Five pictures of the same valence composed a block of 20-second duration. To maintain participants’ attention, a question was presented for 8 seconds after each block regarding the content of 1 of the 5 pictures (e.g., “Was there a red house in the picture?”). After the rating, a fixation cross was shown for 20 seconds. This allowed participants to recover from the previous emotional stimulation and served as a baseline condition. In total, the fMRI paradigm consisted of 16 blocks (8 positive and 8 negative) with an overall duration of 12.8 minutes. The experiment was presented via MRI-compatible video goggles (VisuaStim, Resonance Technology, Inc., Los Angeles, CA, USA) using Presentation software (Neurobehavioral Systems, Inc., Albany, CA, USA). Participants responded by pushing a fiber-optic light-sensitive key press.

Data Acquisition

Functional imaging and in vivo MRS measurements were performed on a Siemens Trio 3T (CHAR) and a Philips Achieva TX 3-T scanner (UZH) using a 32-channel head coil.

Functional images were acquired using T2-weighted standard echo planar imaging sequences. At CHAR data were collected with 37 oblique axial slices of 3 mm (TE = 30 milliseconds; field of view = 192 mm, 3 × 3 mm in-plane resolution, TR = 2000 milliseconds, flip angle 70°) and at UZH with 32 contiguous axial slices of 4 mm (TE = 35 milliseconds; field of view = 220 mm, 2.75 × 2.75 mm in-plane resolution, TR = 2000 milliseconds, flip angle 82°, and sensitivity-encoded acceleration factor R = 2.0). At both scanning sites a 3-dimensional T1-weighted anatomical scan was obtained for structural reference.

For MRS, after a survey scan, at both sites a high-resolution T1-weighted gradient echo image (1 × 1 × 1 mm³) was used for voxel planning and structural reference including tissue segmentation (CHAR: 176 slices, UZH: 160 slices). At CHAR, a single voxel spectroscopy sequence (TR = 3000 milliseconds, TE = 80 milliseconds, number of signal averages = 128, time = 6.5 minutes) was applied with PRESS localization scheme and voxel size of 35 × 20 × 25 mm³ (anterior-posterior [AP], right-left [RL], foot-head [FH]) (AP × RL × FH, 17.5 mL). At UZH, a maximum echo-sampled J-resolved PRESS protocol (as a 2-dimensional echo time series; Schulte et al., 2006; Fuchs et al., 2014) was set up to acquire spectra from a voxel with size of 32 × 21 × 24 mm³ (16.1 mL) in the pgACC (see Figure 1). A minimum echo time of 28 milliseconds and a repetition time of 1600 milliseconds were used. The echo increment to encode the indirect dimension was set to 2 milliseconds, and 100 steps were acquired with NSA = 8 per step (covering TE = [28:226], total NSA = 800, time = 24 minutes). An automatic projection-based second-order B0 shimming routine (Hock et al., 2013), without electrocardiogram triggering), outer volume suppression, and VAPOR water suppression, was achieved (Tkac et al., 1999; Henning et al., 2009).

Figure 1. T1 weighted image of 1 exemplary patient. Color overlays represent segmentation results for grey matter (red), white matter (blue), and cerebrospinal fluid (green). In addition, the voxel placement is shown in yellow (figure created with MRICron, Version 2.9.2019).
Data Analyses

Functional images were pre-processed using MATLAB 2020a (TheMathworks Inc., Natick, MA, USA) and SPM 12 (Statistical parametric mapping software, SPM; Wellcome Department of Imaging Neuroscience, London; UK; http://www.fil.ion.ucl.ac.uk). The data were registered to the mean, corrected for motion artifacts, mean-adjusted by proportional scaling, normalized into standard stereotactic space (template provided by the Montreal Neurological Institute), and spatially smoothed using a 6-mm FWHM Gaussian kernel. The time series were high-pass filtered to eliminate low-frequency components (filter width 128 s) and adjusted for systematic differences across trials. Single-subject analysis was performed by modeling the different conditions (positive picture viewing, negative picture viewing and fixation cross period) convolved with a hemodynamic response function as explanatory variables within the context of the general linear model on a voxel-by-voxel basis. Realignment parameters were included as additional regressors in the statistical model. Region of interest (ROI: x, y, z, in MNI space) analysis was performed to investigate NBRs in the pgACC. We built a spherical ROI (0, 42, 2) with a diameter of 10 mm based on our own previous studies (Grimm et al., 2012; Hartling et al., 2021). For the ROI analysis, contrast images of parameter estimates (emotional picture viewing vs baseline condition) were extracted for each participant separately using the REX toolbox (https://www.nitrc.org/projects/rex/).

MRS data were quantified with LCModel (Figure 2A; version 6.3-1M, CHAR; Provencher, 1993) and Profit2 (Figure 2B; UZH) using a basis set including Glu as 1 of the 21 (CHAR) and 18 (UZH) metabolites (Figure 3). Zero- and first-order phase correction and visual artifact inspection for ghosting, bad water suppression, and line shape distortions was conducted. Based on the high-resolution, 3-dimensional, T1-weighted images, the fractions of cerebrospinal fluid, grey matter, and white matter were calculated using SPM12 and a custom-written MATLAB script including functions from the GANNET framework (Edden et al., 2014). To account for partial volume effects and enable reliable quantification of Glu, the metabolite values were corrected for differences in the tissue volume composition (Gasparovic et al., 2006), including signal differences due to different TRs applied as described in Zoelch et al. (2017) to estimate the metabolite concentrations referenced to the internal water signal (both acquired with PRESS and J-resolved PRESS). As described previously, the absolute concentration estimation raises some difficulties such as the fact that T1 is

Figure 2. (A) Representative spectroscopy data with PRESS localization (TE = 80 milliseconds) and LCModel fitting for the first and second time point. (left): The measured data (blue), the fitted spectrum (red) and the baseline (orange) are shown. (right): The fitted signal contribution of glutamate (Glu) is shown as envelope for the first and second time point. (B) Representative 1-dimensional projections of the 2D JPRESS data and Profit2 fitting for the first and second time point. Left: The measured data (blue), the fitted spectrum (red) and the baseline (orange) are shown for the first and second time point. Right: The 1-dimensional projection of the fitted signal contribution of Glu is shown as envelope for the first and second timepoint.
not available for all metabolites in the basis set, and the absolute concentration is only known for creatine in grey and white matter. Therefore, we added an additional analysis showing simple metabolite over creatine ratios without correction for tissue composition and T1 relaxation time using just the T2-corrected values received from Profit2 (Zoelch et al., 2018). This allowed us to adjust the metabolite concentration for a different gray matter/white matter voxel ratio but also for different relaxation times (resulting in different metabolite signal from different echo times). All metabolite concentrations regardless of the Cramer–Rao lower bound (CRLB) value were included in the statistical analyses (no CRLB threshold was used; Kreis, 2016), with the exception of infinitely high CRLB values (in case a metabolite could not be fitted in a data set) to avoid bias toward higher concentrations. Of note, we did not use CRLBs to deselect measurements, because this might lead to the exclusion of lower concentration metabolites (Kreis, 2016). However, we can report that all Glu measurements in the ACC had CRLBs <7 (PRESS) and 6 (J-resolved PRESS).

Pearson’s correlation analyses were conducted to determine whether pgACC activity prior to ketamine treatment predicted antidepressant effects and to explore the relationship between task-related fMRI signals, percent Glu change in the pgACC, and clinical outcome. Treatment outcome was calculated as percent BDI change. The 2-tailed threshold of significance was set at $P < .05$ unless otherwise noted. Analyses were carried out using SPSS Statistics (Version 25.0. IBM Corp.: Armonk, NY, USA).

**RESULTS**

**Patient and Treatment Characteristics**

In total, 24 patients diagnosed with MDD (14 females) with a mean age of 44.4 years (SD=11.8; range=25–64 years)
participated in the study. Fourteen patients were included at CHAR (mean Montgomery Asberg Depression Rating Scale score = 26.3; SD = 5.1), and 10 patients were included at UZH (mean Hamilton Depression Rating Scale score = 21.8; SD = 4.9). Overall, the mean BDI score at baseline was 34.1 (SD = 11.3) and significantly decreased to 24.7 (SD = 10.0) 24 hours after ketamine administration ($t_{(24)} = 4.1$, $P < .001$). A total 78% of the patients (18/24) showed a reduction of depressive symptoms. The mean clinical improvement was 22.6% (SD = 26.8%). There were no significant differences between patients at the 2 scanning sites (CHAR and UZH) with regard to age ($t_{(22)} = 0.77$; $P = .45$), sex distribution ($x^2 = 0.02; P = .89$), or in their antidepressant response to ketamine as measured by the BDI % change ($t_{(22)} = 0.70; P = .50$).

Current psychopharmacological medication (either as monotherapy or augmentation) included selective serotonin reuptake inhibitors (n = 7), serotonin and norepinephrine reuptake inhibitors (n = 7), tri-/tetracyclic antidepressants (n = 4), anticonvulsants (n = 3), atypical neuroleptics (n = 9), benzodiazepines (n = 6), and melatonin (n = 3). Details of patient characteristics can be found in the Supplement.

### Predicting Clinical Improvement Based on Task-Related pgACC Activity

Patients showed an average NBR in the region of interest, the pgACC, during the presentation of emotional stimuli in the IAPS task. No significant difference in NBRs was found between positive and negative picture viewing ($t_{(22)} = 0.81; P = .43$); therefore, emotional conditions were merged for subsequent analyses.

In line with our hypothesis, we found that pgACC activity during emotional stimulation was a significant predictor of antidepressant outcome to ketamine ($r = 0.35, P < .05$) (Figure 4). More specifically, increased pgACC activity (i.e., reduced NBRs) during the presentation of emotional stimuli in the IAPS task was associated with better clinical outcome 24 hours after the ketamine infusion.

### Relationship Between Functional, Metabolic, and Clinical Parameters

In the subsample of 17 patients undergoing a follow-up MRS scan, we found a significant positive correlation between pgACC activity during the presentation of emotional stimuli in the IAPS task and Glu change in pgACC 24 hours after the ketamine infusion ($r = 0.42, P < .05$). Furthermore, Glu change in pgACC following ketamine administration was significantly associated with treatment outcome ($r = 0.65, P < .005$). More specifically, a stronger Glu increase was related to a better clinical outcome 24 hours after the ketamine infusion.

### Discussion

In this study, we investigated whether the pgACC can serve as a multimodal neuroimaging biomarker of early treatment response to ketamine using both fMRI and MRS in a sample of MDD patients. We were able to show that task-related activity in the pgACC prior to ketamine administration can significantly predict antidepressant effects 24 hours later. Furthermore, pgACC activity during emotional processing prior to treatment was associated with Glu increase 24 hours after the ketamine infusion, which was in turn also related to better clinical outcome.

Our fMRI findings are in line with previous studies demonstrating an association of increased pgACC activity prior to treatment with positive antidepressant response across a variety of antidepressant treatments, neuroimaging modalities, and analytical approaches (Pizzagalli, 2011; Fu et al., 2013; Godlew ska et al., 2018a; Pizzagalli et al., 2018). Based on these findings, the pgACC is currently the best supported candidate for a general neuroimaging biomarker for antidepressant response (Godlew ska, 2020). Similarly, with regard to ketamine it was shown that pgACC activity during emotional and cognitive tasks predicted antidepressant response to ketamine (Salvadore et al., 2009, 2010). It has been proposed that the increased activity state of the pgACC may represent its treatment-responsive mode and be specifically important for clinical effects of rapid-acting glutamatergic drugs such as ketamine (Downey et al., 2016; Chadi G. Abdallah et al., 2017a; Godlew ska, 2020). This hypothesis is supported by our finding of an association of pgACC activity with both symptom improvement and Glu increase 24 hours after the ketamine infusion. As the pgACC is part of the DMN (Raichle et al., 2001), it can further be suggested that its aberrant activation with decreased NBRs during emotional stimulation indicates that depressed patients, who are less able to disengage their DMN and actively engage with emotional stimuli, are more likely to respond to ketamine treatment.

Our investigation of biomarkers across different modalities, that is, pgACC activity during emotional processing and Glu concentration, might thereby serve as a useful approach to optimize prediction of treatment response to ketamine. Although previous studies exploring single neuroimaging markers of antidepressant response to ketamine hold considerable promise (for a review, see Kadriu et al., 2020), multimodal technologies offer significant advantages but have previously mainly been used to better understand mechanisms of action underlying ketamine administration (Niciu et al., 2017; Evans et al., 2018; Nugent et al., 2019; Li et al., 2020; McMillan et al., 2020).

The role of Glu in the pathophysiology of depression as well as the rapid relief of depressive symptoms by Glu modulation have been demonstrated by preclinical and clinical studies (Sanacora et al., 2012; Chadi G. Abdallah et al., 2015; Lener et al., 2017). Depressive states are accompanied by glutamatergic system alterations such as decreased expression of NMDA and AMPA receptor subunits as well as decreased number of neurons (Rajkowska et al., 1999; Pittenger and Duman, 2008; Feyissa et al., 2009; Duman and Aghajanian, 2012; Yuen et al., 2012). While meta-analyses have generally reported diminished levels of Glu in depression (Luykx et al., 2012; Arnone et al., 2015; Moriguchi et al., 2019), data from individual studies are inconsistent and there are also reports of no differences or even increased Glu levels in MDD (Taylor et al., 2012; Chadi
Accordingly, it has been discussed whether different profiles of glutamatergic dysregulation might be related to MDD severity or course, with high concentrations of Glu in the early illness phase being followed by lower levels as a result of neurotoxic effects on Glu neurotransmission (Portella et al., 2011; Arnone et al., 2015; Haroon et al., 2018; Hasler et al., 2019). Reduced concentrations of Glu in pgACC (Shirayama et al., 2017; Wise et al., 2018; Benson et al., 2020) might thereby eventually contribute to emotional dysregulation and perseverative rumination in MDD (Johansen-Berg et al., 2008; Pizzagalli, 2011). Indeed, Horn et al. (2010) found that only more severely depressed patients showed reduced Glu levels. Given that depression severity prior to ketamine treatment in the investigated sample was comparable, our data support hypoglutamatergic function in depression and a ketamine-induced increase in Glu that subsequently triggers improvement of depressive symptoms. Decreased pgACC Glu content normalizes after diverse antidepressant treatments such as ECT, antidepressants, and rTMS (Pfeifer et al., 2003; Luborzewski et al., 2007; Zhang et al., 2013; Yang et al., 2014; Njau et al., 2017) and might thereby represent a shared biological pathway (Skolnick, 1999). Our findings support the hypothesis that a perturbation of the Glu system in pgACC is critically implicated in MDD and treatment changes (Pizzagalli, 2011) and may be an essential mechanistic step in antidepressant response across treatment modalities. However, the timing of this perturbation may differ between treatments. Specifically, clinical response to ketamine may depend on a rapid change in pgACC Glu concentration. In contrast, treatment with antidepressants, ECT, and rTMS may have cumulative effects on the Glu system that are detectable weeks after initiation of treatment (Brennan et al., 2010).

Administration of ketamine has been found to result in a surge of Glu and increase in Glu/Clin cycling (Chowdhury et al., 2017), and previous 1H magnetic Resonance Spectroscopy (1H-MRS) investigations noted increased glutamatergic metabolite levels in healthy volunteers (Rowland et al., 2005; Stone et al., 2012) and increased Glx levels in MDD patients (Milak et al., 2016) following acute ketamine administration. Abdallah et al. (Abdallah et al., 2018) reported that ketamine increased prefrontal Glu-Gln cycling, thereby providing the most direct evidence in humans that ketamine increases Glu release in the prefrontal cortex, a mechanism implicated in the induction of rapid antidepressant effects. Milak et al. (Milak et al., 2016; Milak et al., 2020) found that Glu/Gln changes occur within the first 30–40 minutes postketamine administration in the pgACC, which supports the idea that the Glu burst happens quite early postketamine infusion (Javitt et al., 2018). Increased Glu concentration after ketamine has been linked to NMDA receptor inhibition and subsequent AMPA receptor activation (Rowland et al., 2005; Stone et al., 2012; Zanos et al., 2016). Interestingly, pgACC exhibits above average AMPA and below average NMDA receptor densities (compared with whole cingulate cortex) (Palomero-Gallagher et al., 2009) and regional variations of Glu concentration follow these receptor fingerprints (Dou et al., 2013). Accordingly, our result of a significant Glu response to a single subanesthetic dose of ketamine may be associated with the histoarchitectonical receptor fingerprint of the pgACC.

However, there are also investigations that found no effect of ketamine on Glu concentration 1 hour postketamine infusion in healthy volunteers (Taylor et al., 2012), or 3 and 48 hours later in MDD patients (Valentine et al., 2011). Also, Evans et al. (2018) reported that ketamine did not affect Glu levels in the pgACC in MDD patients and that antidepressant response was not predicted by baseline Glu levels. Variations in voxel location, timing of the scan, imaging parameters, and sample size may explain these discrepant findings.

There are several limitations to this study. Our study sample was relatively small, and results will benefit from further replication in larger studies as well as in more homogeneous samples of unmedicated patients. However, previous MRS studies investigating pgACC activity as a single neuroimaging biomarker of clinical response to ketamine included even smaller numbers of patients (n = 11, Salvadore et al., 2009; n = 15, Salvadore et al., 2010). Furthermore, considering the ongoing debate on antidepressant placebo outcomes (Holper, 2020), the lack of a placebo group in our study might imply that the reported pgACC activations predicted spontaneous improvement and are not directly linked to the effects of ketamine. However, this is unlikely, as previous work showed robust differences in clinical effects between ketamine and placebo (Berman et al., 2000). In addition, the current study was underpowered to assess the impact of psychopharmacological medication on neuroimaging data in our group of 24 depressed patients with heterogeneous medication intake. As medication has been shown to influence many neuroimaging findings (e.g., Hafeman et al., 2012), higher-powered studies should control for and explore interactions with medication. Also, our primary aim was to link imaging biomarkers to symptom improvement after ketamine treatment, and we therefore argue that conclusions can be drawn from our analyses without a placebo condition. It should be considered that the reported data were obtained at 2 study sites and that the procedures at both sites were slightly different, with patients at UZH receiving S-ketamine and at CHAR racemic ketamine. Racemic ketamine is the mixture of the enantiomers R-ketamine and S-ketamine. However, consistent with our results, racemic ketamine and esketamine were shown to have similar antidepressant efficacy (Zanos et al., 2018). Another limitation is that we did not obtain MRS measures of Gln and GABA in the current study due to technical issues. Future studies should try to measure the concentrations of these additional metabolites in the pgACC to further investigate a possible relationship to antidepressant response.

In conclusion, our results not only provide insights into the relationship between pgACC activity, glutamatergic neurotransmission, and clinical outcome but support increasing evidence suggesting that the pgACC can serve as a biomarker to predict antidepressant effects across a variety of treatments. Particularly the combination of biomarkers across different modalities might optimize prediction of treatment response to ketamine.

Acknowledgments

The authors thank Luisa Bönke, Marvin Sören Meiering, David Weigner, and Vivien Hajak for their support in the bibliography update.

This work was funded by the European Commission (grant no. H2020–634541).

Author’s Contributions

A.W. analyzed the data and wrote the manuscript; M.G. analyzed the data and wrote the manuscript; M.S. designed the study and acquired the data; P.W. analyzed the data; A.H. designed the study; E.S. designed the study; A.S. acquired and analyzed the data; A.H.M. acquired the data; M.B. designed the
study; S.A. designed the study and acquired the data; S.G. designed the study and wrote the manuscript. All authors revised and approved the final version of the manuscript.

**Interest Statement**

Malek Bajbouj was involved in a clinical trial by Johnson and Johnson investigating the antidepressant effects of ketamine. Simone Grimm has served as a consultant to and received research support from Boehringer Ingelheim Pharma.

**References**

Abdallah CG, Averill LA, Kristal JH (2015) Ketamine as a promising prototype for a new generation of rapid-acting antidepressants. Ann N Y Acad Sci 1344:66–77.

Abdallah CG, Averill LA, Collins KA, Ghea P, Schwartz J, Averill C, DeWilde KE, Wong E, Anticevic A, Tang CY, Isosfescu DV, Charney DS, Murrough JW (2017a) Ketamine treatment and global brain connectivity in major depression. Neuropsychopharmacology 42:1210–1219.

Abdallah CG, Hannestad J, Mason GF, Holmes SE, DellaGioia N, Sanacora G, Jiang L, Matuskey D, Salaniya R, Gasparini F, Lin X, Javitch J, Planeta B, Nabulsi N, Carson RE, Esterlis I (2017b) Metabolic glutamate receptor 5 and glutamate concentrations follow receptor fingerprints of human cingulate cortex. J Neurosci 33:12698–12704.

Downey D, Dutta A, McKe S, Dawson GR, Doulish CT, Craig K, Smith MA, McCarthy DJ, Harmer CJ, Goodwin GM, Williams S, Deakin JFW (2016) Comparing the actions of lamotrigine and ketamine in depression: key role of the anterior cingulate. Eur Neuropsychopharmacol 26:994–1003.

Drevets WC, Switz J, Trimble M (2008) The subgenual anterior cingulate cortex in mood disorders. CNS Spectr 13:663–681.

Duman RS, Aghajanian GK (2012) Synchrony dysfunction in depression: potential therapeutic targets. Science 338:68–72.

Edden RAE, Puts NAJ, Harris AD, Barker PB, Evans CJ (2014) Gabbit: a batch-processing tool for the quantitative analysis of gamma-aminobutyric acid-edited MR spectroscopy spectra: Gabbit: GABA Analysis Toolkit. J Magn Res Imaging 40:1445–1452.

Evans JW, Lally N, An L, Li N, Nugent AC, Banerjee D, Snider SI, Shen J, Roiser JP, Zarate CA (2018) 7T 1H-MRS in major depressive disorder: a ketamine treatment study. Neuropsychopharmacology 43:1908–1914.

Feyissa AM, Chandran A, Stockmeier CA, Karolewicz B (2009) Reduced levels of NR2A and NR2B subunits of NMDA receptor and PSD-95 in the prefrontal cortex in major depression. Prog Neuropsychopharmacol Biol Psychiatry 33:70–75.

Fu CHY, Steiner H, Castafreda SG (2013) Predictive neural biomarkers of clinical response in depression: a meta-analysis of functional and structural neuroimaging studies of pharmacological and psychological therapies. Neurobiology Dis 52:75–83.

Fuchs A, Boesiger P, Schulte RF, Henning A (2014) ProFit revisited. Magn Reson Med 71:458–468.

Gasparovic C, Song T, Devier D, Bockholt HJ, Caprihan A, Mullins PG, Posse S, Jung RE, Morrison LA (2006) Use of tissue water as a concentration reference for proton spectroscopic imaging. Magn Reson Med 55:1219–1226.

Godfrey KEM, Gardner AC, Kwon S, Chea W, Muthukumaraswamy SD (2018) Differences in excitatory and inhibitory neurotransmitter levels between depressed patients and healthy controls: a systematic review and meta-analysis. J Psychiatr Res 105:33–44.

Godlewkska BR (2020) Neuroimaging as a tool for individualized treatment choice in depression: the past, the present and the future. Curr Behav Neurosci Rep 7:32–39.

Godlewkska BR, Browning M, Norbury R, Igoumenou A, Cowen PJ, Harmer CJ (2018a) Predicting treatment response in depression: the role of anterior cingulate cortex. Int J Neuropsychopharmacol 21:988–996.

Godlewkska BR, Masaki C, Sharpely AL, Cowen PJ, Emir UE (2018b) Brain glutamate in medication-free depressed patients: a proton MRS study at 7 Tesla. Psychol Med 48:1731–1737.

Grimm S, Ernst J, Boesiger P, Schuepbach D, Boeker H, Northoff G (2011) Reduced negative BOLD responses in the default-mode network of depressed patients: a voxel-based meta-analysis. Neuroimage 54:772–783.

Chowdhury GMI, Zhang J, Thomas M, Banasr M, Ma X, Pittman B, Bristow L, Schaeffer E, Duman RS, Rothman DL, Behar KL, Sanacora G (2017) Transiently increased glutamate cycling in rat PFC is associated with rapid onset of antidepressant-like effects. Mol Psychiatry 22:120–126.
network and increased self-focus in depression. World J Biol Psychiatry 12:627–637.

Grimm S, Weigand A, Kазzer P, Jacobs AM, Bajbouj M (2012) Neural mechanisms underlying the integration of emotion and working memory. NeuroImage 61:1188–1194.

Hafeman DM, Chang KD, Garrett AS, Sanders EM, Phillips ML (2012) Effects of medication on neuroimaging findings in bipolar disorder: an updated review. Bipolar Disord 14:375–410.

Hamilton M (1980) Rating depressive patients. J Clin Psychiatry 41:21–24.

Haroon E, Chen X, Li Z, Patel T, Woolwine BJ, Hu XP, Felger JC, Miller AH (2018) Increased inflammation and brain glutamate define a subtype of depression with decreased regional homogeneity, impaired network integrity, and anhedonia. Transl Psychiatry 8:189.

Hartling C, Metz S, Pehrs C, Scheidegger M, Gruzman R, Keicher C, Wunder A, Weigand A, Grimm S (2021) Comparison of four fMRI paradigms probing emotion processing. Brain Sci 11:525.

Hashimoto K (2019) Rapid-acting antidepressant ketamine; its metabolites and other candidates: a historical overview and future perspective. Psychiatry Clin Neurosci 73:613–627.

Hasler G, Buchmann A, Haynes M, Müller ST, Ghisleni C, Brechbühl S, Tuura R (2019) Association between prefrontal glutamate levels and neuroticism determined using proton magnetic resonance spectroscopy. Transl Psychiatry 9:170.

Henning A, Fuchs A, Murdoch JB, Boesiger P (2009) Slice-selective FID acquisition, localized by outer volume suppression (FIDLOVS) for 1H-MRSI of the human brain at 7 T with minimal signal loss. NMR Biomed 22:683–696.

Hock A, Fuchs A, Boesiger P, Kollias SS, Henning A (2011) Electrocardiogram-triggered, higher order, projection-based B0 shimming allows for fast and reproducible shim convergence in spinal cord 1H MRS. NMR Biomed 26:329–335.

Holper L (2020) Raising placebo efficacy in antidepressant trials across decades explained by small-study effects: a meta-reanalysis. Front Psychiatry 11:633.

Horn ID, Yu C, Steiner J, Buchmann J, Kaufmann J, Osoba A, Eckert U, Zierhut KC, Schiltz K, He H, Biswal B, Bogerts B, Walter M (2010) Glutamatergic and resting state functional connectivity correlates of severity in major depression - the role of pregenual anterior cingulate cortex and anterior insula. Front Syst Neurosci 4:1–10.

Javitt DC, et al. (2018) Utility of imaging-based biomarkers for glutamate-targeted drug development in psychiatric disorders: a randomized clinical trial. JAMA Psychiatry 75:11–19.

Johansen-Berg H, Gutman DA, Behrens TEJ, Matthews PM, Rushworth MFS, Katz E, Lozano AM, Mayberg HS (2008) Anatomical connectivity of the subgenual cingulate region targeted with deep brain stimulation for treatment-resistant depression. Cereb Cortex 18:1374–1383.

Kadriu B, Ballard ED, Henter ID, Murata S, Gerlus N, Zarate CA (2020) Neurobiological biomarkers of response to ketamine. Adv Pharmacol 89:195–235.

Kreis R (2016) The trouble with quality filtering based on relative Cramér-Rao lower bounds. Magn Reson Med 75:15–18.

Lang PJ, Bradley MM, Cuthbert BN (1997) International Affective Picture System (IAPS): technical manual and affective ratings, Vol. 1. NIMH Center for the Study of Emotion and Attention, 39–58. Gainesville, FL: University of Florida.

Lehmann M, Seifritz E, Henning A, Walter M, Böker H, Scheidegger M, Grimm S (2016) Differential effects of rumination and distraction on ketamine induced modulation of resting state functional connectivity and reactivity of regions within the default-mode network. Soc Cogn Affect Neurosci 11:1227–1235.

Lener MS, Niciu MJ, Ballard ED, Park M, Park LT, Nugent AC, Zarate CA (2017) Glutamate and gamma-aminobutyric acid systems in the pathophysiology of major depression and antidepressant response to ketamine. Biol Psychiatry 81:886–897.

Li M, Metzger CD, Li W, Safron A, van Tol M-J, Lord A, Krause AL, Borchardt V, Dou V, Genz A, Heinez H-J, He H, Walter M (2014) Dissociation of glutamate and cortical thickness is restricted to regions subserving trait but not state markers in major depressive disorder. J Affect Disord 169:91–100.

Li M, Demenescu LR, Colic L, Metzger CD, Heinez H-J, Steiner J, Speck O, Fejtova A, Salvador G, Walter M (2017) Temporal dynamics of antidepressant ketamine effects on glutamine cycling follow regional fingerprints of AMPA and NMDA receptor densities. Neuropsychopharmacology 42:1201–1209.

Li M, Woelfer M, Colic L, Safron A, Chang C, Heinez H-J, Speck O, Mayberg HS, Biswal BB, Salvador G, Fejtova A, Walter M (2020) Default mode network connectivity change corresponds to ketamine’s delayed glutamatergic effects. Eur Arch Psychiatry Clin Neurosci 270:207–216.

Luborzewski A, Schubert F, Seifert F, Danker-Hopfe H, Brakemeier E-L, Schlattmann P, Angelescu I, Colla M, Bajbouj M (2007) Metabolic alterations in the dorsolateral prefrontal cortex after treatment with high-frequency repetitive transcranial magnetic stimulation in patients with unipolar major depression. J Psychiatr Res 41:606–615.

Luyckx JJ, Laban KG, van den Heuvel MP, Boks MP, Mandl RCW, Kahn RS, Bakker SC (2012) Region and state specific glutamate downregulation in major depressive disorder: a meta-analysis of 1H-MRS findings. Neurosci Biobehav Rev 36:198–205.

McMillan R, Sumner R, Forsyth A, Campbell DJ, Malpas G, Maxwell E, Deng C, Hay J, Ponton R, Sundram F, Muthukumaraswamy S (2020) Simultaneous EEG/fMRI recorded during ketamine infusion in patients with major depressive disorder. Prog Neuropsychopharmacol Biol Psychiatry 99:109838.

Milak MS, Proper CJ, Mulhern ST, Parter AL, Kegeles LS, Dong Z, Grunebaum MF, Bajbouj M (2007) Metabolic alterations in the dorsolateral prefrontal cortex after treatment with high-frequency repetitive transcranial magnetic stimulation in patients with unipolar depression: a randomized clinical trial. JAMA Network Open 3:e2013211.

Montgomery SA, Åsberg M (1979) A new depression scale designed to be sensitive to change. Br J Psychiatry 134:382–389.

Moriguchi S, et al (2019) Glutamatergic neurometabolite levels in major depressive disorder: a systematic review and meta-analysis of proton magnetic resonance spectroscopy studies. Mol Psychiatry 24:952–964.

Niciu MJ, Iadarola ND, Banerjee D, Luckenbaugh DA, Park M, Lener M, Park L, Ionescu DF, Ballard ED, Brutsche NE, Akula N, McMahon FJ, Machado-Vieira R, Nugent AC, Zarate CA (2017) The antidepressant efficacy of subanesthetic-dose ketamine does not correlate with baseline subcortical volumes in a replication sample with major depressive disorder. J Psychopharmacol 31:1570–1577.
Njau S, Joshi SH, Espinoza R, Leaver AM, Vasavada M, Marquina A, Woods RF, Narr KL (2017) Neurochemical correlates of rapid treatment response to electroconvulsive therapy in patients with major depression. J Psychiatry Neurosci 42:6–16.

Nugent AC, Ballard ED, Gould TD, Park LT, Moaddel R, Brutsche NE, Zarate CA (2019) Ketamine has distinct electrophysiological and behavioral effects in depressed and healthy subjects. Mol Psychiatry 24:1040–1052.

Palomero-Gallagher N, Vogt BA, Schleicher A, Mayberg HS, Zilles K (2009) Receptor architecture of human cingulate cortex: evaluation of the four-region neurobiological model. Hum Brain Mapp 30:2336–2355.

Pfeiderer B, Michael N, Erfurth A, Ohrmann P, Hohmann U, Wolgast M, Fiebich B, Arolt V, Heindel W (2003) Effective electroconvulsive therapy reverses glutamate/glutamine deficit in the left anterior cingulum of unipolar depressed patients. Psychiatry Res Neuroimaging 122:185–192.

Pittenger C, Duman RS (2008) Stress, depression, and neuroplasticy: a convergence of mechanisms. Neuropsychopharmacology 33:88–109.

Pizzagalli DA (2011) Frontocingulate dysfunction in depression: toward biomarkers of treatment response. Neuropsychopharmacology 36:183–206.

Pizzagalli DA, Webb CA, Dillon DG, Tenke CE, Kayser J, Goer F, Fava M, McGrath P, Weissman M, Parsey R, Adams P, Trombello J, Cooper C, Deldin P, Oquendo MA, McInnis MG, Carmody T, Bruder G, Trivedi MH (2018) Pretreatment rostral anterior cingulate cortex theta activity in relation to symptom improvement in depression: a randomized clinical trial. JAMA Psychiatry 75:547–554.

Portella MJ, de Diego-Adelino J, Gómez-Ansón B, Morgan-Ferrando R, Vives Y, Puigdemont D, Pérez-Egea R, Ruscalleda J, Álvarez E, Pérez V (2011) Ventromedial prefrontal spectroscopic abnormalities over the course of depression: a comparison among first episode, remitted recurrent and chronic patients. J Psychiatr Res 45:427–434.

Provencher SW (1993) Estimation of metabolite concentrations from localized in vivo proton NMR spectra. Magn Reson Med 30:672–679.

Raichle ME, MacLeod AM, Snyder AZ, Powers WJ, Gusnard DA, Shulman GL (2001) A default mode of brain function. PNAS 98:676–682.

Rajkowski G, Miguel-Hidalgo JJ, Wei J, Dilley G, Pittman SD, Meltzer HY, Overholser JC, Roth BL, Stockmeier CA (1999) Morphometric evidence for neuronal and glial prefrontal cell pathology in major depression. Biol Psychiatry 45:1085–1098.

Rowland LM, Bustillo JR, Mullins PG, Jung RE, Lenroot R, Landgraf E, Barrow R, Yeo R, Lauriello J, Brooks WM (2005) Effects of ketamine on anterior cingulate glutamate metabolism in healthy humans: a 4-T proton MRS study. Am J Psychiatry 162:394–396.

Salvadore G, Cornwell BR, Colon-Rosario V, Coppola R, Grillon C, Zarate CA, Manji HK (2009) Increased anterior cingulate cortical activity in response to fearful faces: a neurophysiological biomarker that predicts rapid antidepressant response to ketamine. Biol Psychiatry 65:289–295.

Salvadore G, Cornwell BR, Sambataro F, Latov D, Colon-Rosario V, Carver F, Holroyd T, DiazGranados N, Machado-Vieira R, Grillon C, Drevets WC, Zarate CA (2010) Anterior cingulate desynchronization and functional connectivity with the amygdala during a working memory task predict rapid antidepressant response to ketamine. Neuropsychopharmacology 35:1415–1422.

Sanacora G, Treccani G, Popoli M (2012) Towards a glutamate hypothesis of depression. Neuropsychopharmacology 62:65–77.

Schulte RF, Lange T, Beck J, Meier D, Boesiger P (2006) Improved two-dimensional J-resolved spectroscopy. NMR Biomed 19:264–270.

Sheline YI, Barch DM, Price JL, Rundle MM, Vaishnavi SN, Snyder AZ, Mintun MA, Wang S, Coalson RS, Raichle ME (2009) The default mode network and self-referential processes in depression. PNAS 106:1942–1947.

Shirayama Y, Takahashi M, Osone F, Hara A, Okubo T (2017) Myo-inositol, glutamate, and glutamine in the prefrontal cortex, hippocampus, and amygdala in major depression. Biol Psychiatry Cogn Neurosci Neuroimaging 2:196–204.

Sinner B, Graf BM (2008) Ketamine. In: Modern anesthetics (Schüttler J, Schiöth H, eds), pp313–333. Berlin, Heidelberg: Springer.

Skolnick P (1999) Antidepressants for the new millennium. Eur J Pharmacol 375:31–40.

Stone JM, Dietrich C, Edden R, Mehta MA, De Simoni S, Reid LJ, Krystal JH, Nutt D, Barker GJ (2012) Ketamine effects on brain GABA and glutamate levels with 1H-MRS: relationship to ketamine-induced psychopathology. Mol Psychiatry 17:664–665.

Taylor MJ, Tiangga ER, Mhiurcheartaigh RN, Cowen PJ (2012) Lack of effect of ketamine on cortical glutamate and glutamine in healthy volunteers: a proton magnetic resonance spectroscopy study. J Psychopharmacol 26:733–737.

Tkac I, Starck Z, Choi Y, Gruetter R (1999) In vivo 1H NMR spectroscopy of rat brain at 1 ms echo time. Magn Reson Med 41:649–656.

Valentine GW, Mason GF, Gomez R, Fasula M, Watzl J, Pittman K, Krystal JH, Sanacora G (2011) The antidepressant effect of ketamine is not associated with changes in occipital amino acid neurotransmitter content as measured by [1H]-MRS. Psychiatry Res Neuroimaging 191:122–127.

Walter M, Henning A, Grimm S, Schulte RF, Beck J, Dydak U, Schnefp B, Boeker H, Boesiger P, Northoff G (2009) The relationship between aberrant neuronal activation in the pregenual anterior cingulate, altered glutamatergic metabolism, and anhedonia in major depression. Arch Gen Psychiatry 66:478–486.

Wise T, Taylor MJ, Herane-Vives A, Gammazza AM, Cappello F, Lythgoe DJ, Williams SCR, Young AH, Cleare AJ, Arnone D (2018) Glutamatergic hypofunction in medication-free major depression: secondary effects of affective diagnosis and relationship to peripheral glutaminase. J Affect Disord 234:212–219.

Yang X-R, Kirton A, Wilkes TC, Pradhan S, Liu I, Jaworska N, Damji O, Keess J, Langevin LM, Rajapakse T, Lebel RM, Sembo M, Fife M, MacMaster FP (2014) Glutamate alterations associated with transcranial magnetic stimulation in youth depression: a case series. J ECT 30:242–247.

Yuen Eunice Y, Wei J, Liu W, Zhong P, Li X, Yan Z (2012) Repeated ketamine reduces cortical glutamate at the NMDA receptor and increases prefrontal glutamine: two-dimensional J-resolved spectroscopy. NMR Biomed 25:532–542.

Zanos P, Moaddel R, Morris PJ, Georgiou P, Fischell J, Elmer GI, Alkondon M, Yuan P, Pribut HJ, Singh NS, Dossou KSS, Fang Y, Huang XP, Mayo CL, Wainer IW, Albuquerque EX, Thompson SM, Thomas CJ, Zarate Jr CA, Gould TD (2016)
NMDAR inhibition-independent antidepressant actions of ketamine metabolites. Nature 533:481–486.
Zanos P, Moaddel R, Morris PJ, Riggs LM, Highland JN, Georgiou P, Pereira EFR, Albuquerque EX, Thomas C J, Zarate CA, Gould TD (2018) Ketamine and ketamine metabolite pharmacology: insights into therapeutic mechanisms. Pharmacol Rev 70:621–660.
Zarate CA, Singh JB, Carlson PJ, Brutsche NE, Ameli R, Luckenbaugh DA, Charney DS, Manji HK (2006) A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry 63:856–864.
Zhang J, Narr KL, Woods RP, Phillips OR, Alger JR, Espinoza RT (2013) Glutamate normalization with ECT treatment response in major depression. Mol Psychiatry 18:268–270.
Zoelch N, Hock A, Heinzer-Schweizer S, Avdievitch N, Henning A (2017) Accurate determination of brain metabolite concentrations using ERETIC as external reference. NMR Biomed 30:e3731.
Zoelch N, Hock A, Henning A (2018) Quantitative magnetic resonance spectroscopy at 3T based on the principle of reciprocity. NMR Biomed 31:e3875.